Nationwide Fund Advisors lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 2.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,451 shares of the company’s stock after selling 3,929 shares during the quarter. Nationwide Fund Advisors owned approximately 0.28% of LivaNova worth $9,420,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its holdings in shares of LivaNova by 9.8% during the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after acquiring an additional 153 shares during the last quarter. Riverhead Capital Management LLC raised its holdings in shares of LivaNova by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after acquiring an additional 763 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of LivaNova in the second quarter valued at approximately $204,000. Martingale Asset Management L P purchased a new stake in shares of LivaNova in the second quarter valued at approximately $221,000. Finally, Bessemer Group Inc. purchased a new stake in shares of LivaNova in the second quarter valued at approximately $220,000. 86.07% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on LIVN shares. Jefferies Group started coverage on LivaNova in a research report on Friday, September 8th. They issued a “buy” rating and a $76.00 price target for the company. Needham & Company LLC upgraded LivaNova from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research report on Friday, September 15th. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $75.00 price target on shares of LivaNova in a research report on Tuesday, September 12th. Finally, WBB Securities lowered LivaNova from a “hold” rating to a “sell” rating and set a $50.00 price target for the company. in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. LivaNova presently has a consensus rating of “Buy” and an average target price of $79.71.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $74.58, for a total value of $74,580.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hugh M. Morrison sold 1,830 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. Insiders sold 6,830 shares of company stock valued at $557,100 over the last quarter. 0.28% of the stock is currently owned by company insiders.
Shares of LivaNova PLC (NASDAQ LIVN) opened at $83.73 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. The stock has a market capitalization of $3,989.02, a P/E ratio of 23.84, a PEG ratio of 2.48 and a beta of 0.61. LivaNova PLC has a 52-week low of $44.58 and a 52-week high of $88.56.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.17. The business had revenue of $309.70 million during the quarter, compared to analyst estimates of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.78 earnings per share. sell-side analysts predict that LivaNova PLC will post 3.33 EPS for the current fiscal year.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.